Shih-Hong Chen1,2,3, Li-Kuei Chen4,5, Tsung-Han Teng6, Wei-Han Chou1. 1. Department of Anesthesiology, National Taiwan University Hospital, Taipei City, Taiwan. 2. Department of Anesthesiology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan. 3. Institute of Molecular Medicine, National Tsing Hua University, Hsinchu, Taiwan. 4. Anesthesiology Department of China Medical University, Taichung City, Taiwan. 5. Anesthesiology Department of China Medical University Hospital, Taichung City, Taiwan. 6. Department of Pathology, St. Martin De Porres Hospital, Chiayi City, Taiwan.
Abstract
Background: This study aims to compare the effectiveness of inhaled prostacyclin or its analoguesversus nitric oxide (NO) in treating pulmonary hypertension (PH) after cardiac or pulmonary surgery remains unclear. Methods: PubMed, Cochrane, and Embase databases were searched for literature published prior to December 2019 using the following keywords: inhaled, nitric oxide, prostacyclin, iloprost, treprostinil, epoprostenol, Tyvaso, flolan, and pulmonary hypertension. Randomized controlled trials and multiple-armed prospective studies that evaluated inhaled NO versus prostacyclin (or analogues) in patients for perioperative and/or postoperative PH after either cardiac or pulmonary surgery were included. Retrospective studies, reviews, letters, comments, editorials, and case reports were excluded. Results: Seven studies with a total of 195 patients were included. No difference in the improvement of mean pulmonary arterial pressure (pooled difference in mean change= -0.10, 95% CI: -3.98 to 3.78, p = .959) or pulmonary vascular resistance (pooled standardized difference in mean change= -0.27, 95% CI: -0.60 to 0.05, p = .099) were found between the two treatments. Similarly, no difference was found in other outcomes between the two treatments or subgroup analysis.Conclusions: Inhaled prostacyclin (or analogues) was comparable to inhaled NO in treating PH after cardiac or pulmonary surgery.Key messagesThis study compared the efficacy of inhaled prostacyclin or its analogues versus inhaled NO to treat PH after surgery. The two types of agent exhibited similar efficacy in managing MPAP, PVR, heart rate, and cardiac output was observed.Inhaled prostacyclin may serve as an alternative treatment option for PH after cardiac or pulmonary surgery.
Background: This study aims to compare the effectiveness of inhaled prostacyclin or its analoguesversus nitric oxide (NO) in treating pulmonary hypertension (PH) after cardiac or pulmonary surgery remains unclear. Methods: PubMed, Cochrane, and Embase databases were searched for literature published prior to December 2019 using the following keywords: inhaled, nitric oxide, prostacyclin, iloprost, treprostinil, epoprostenol, Tyvaso, flolan, and pulmonary hypertension. Randomized controlled trials and multiple-armed prospective studies that evaluated inhaled NO versus prostacyclin (or analogues) in patients for perioperative and/or postoperative PH after either cardiac or pulmonary surgery were included. Retrospective studies, reviews, letters, comments, editorials, and case reports were excluded. Results: Seven studies with a total of 195 patients were included. No difference in the improvement of mean pulmonary arterial pressure (pooled difference in mean change= -0.10, 95% CI: -3.98 to 3.78, p = .959) or pulmonary vascular resistance (pooled standardized difference in mean change= -0.27, 95% CI: -0.60 to 0.05, p = .099) were found between the two treatments. Similarly, no difference was found in other outcomes between the two treatments or subgroup analysis.Conclusions: Inhaled prostacyclin (or analogues) was comparable to inhaled NO in treating PH after cardiac or pulmonary surgery.Key messagesThis study compared the efficacy of inhaled prostacyclin or its analogues versus inhaled NO to treat PH after surgery. The two types of agent exhibited similar efficacy in managing MPAP, PVR, heart rate, and cardiac output was observed.Inhaled prostacyclin may serve as an alternative treatment option for PH after cardiac or pulmonary surgery.
Authors: G D Rocca; C Coccia; L Pompei; F Ruberto; F Venuta; T De Giacomo; P Pietropaoli Journal: J Cardiothorac Vasc Anesth Date: 2001-04 Impact factor: 2.628
Authors: Khalil Fattouch; Fabrizio Sbraga; Roberta Sampognaro; Giuseppe Bianco; Marco Gucciardo; Carlo Lavalle; Carmine Dario Vizza; Francesco Fedele; Giovanni Ruvolo Journal: J Cardiovasc Med (Hagerstown) Date: 2006-02 Impact factor: 2.160
Authors: Juan C Bianco; Santiago Mc Loughlin; André Y Denault; Ricardo G Marenchino; Juan I Rojas; Francisco C Bonofiglio Journal: J Cardiothorac Vasc Anesth Date: 2017-09-18 Impact factor: 2.628
Authors: Tsvetomir Loukanov; Dietrich Bucsenez; Wolfgang Springer; Christian Sebening; Helmut Rauch; Eva Roesch; Matthias Karck; Matthias Gorenflo Journal: Clin Res Cardiol Date: 2011-02-13 Impact factor: 5.460
Authors: Julian P T Higgins; Douglas G Altman; Peter C Gøtzsche; Peter Jüni; David Moher; Andrew D Oxman; Jelena Savovic; Kenneth F Schulz; Laura Weeks; Jonathan A C Sterne Journal: BMJ Date: 2011-10-18